Hydrocortisone Sodium Phosphate
FDA-approved product (injectable, injection), marketed as Hydrocortone.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Adrenal gland disease
- Adrenocortical insufficiency
- Allergic conjunctivitis
- Asthma
- Atopic eczema
- Bursitis
- Cancer
- Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- Congenital adrenal hyperplasia
- Crohn's disease
- Dermatitis
- Endocrine system disease
- Exanthem
- Eye inflammation
- Hemorrhoid
- Herpes Labialis
- and 19 more
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Hydrocortisone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
NCT00440726 · start 2006-08-04
Registered record
- Registry ID
- NCT00440726
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Bortezomib; Dexamethasone; PEG-asparaginase; Doxorubicin; Cytarabine; Methotrexate; Vincristine; Triple IT Therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2006-08-04
- Completion
- 2011-02-26
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic LeukemiaInterventionBortezomib; Dexamethasone; PEG-asparaginase; Doxorubicin +4 morePhasePhase 1 / Phase 2Registry statusCompletedThe Importance of Adrenomedullin (AM) on ACTH-Cortisol-Glucose Axis
NCT00459511 · start 2006-01
Registered record
- Registry ID
- NCT00459511
- Conditions
- Systemic Inflammatory Response Syndrome; Hyperglycemia
- Interventions
- Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2006-01
- Completion
- 2006-10
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSystemic Inflammatory Response Syndrome; HyperglycemiaInterventionBlood AM, IL-6, ACTH, Cortisol, Glucose and InsulinPhaseNot recordedRegistry statusCompletedCorticosteroid Therapy of Septic Shock - Corticus
NCT00147004 · start 2002-03
Registered record
- Registry ID
- NCT00147004
- Conditions
- Shock, Septic
- Interventions
- hydrocortisone sodium succinate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-03
- Completion
- 2005-11
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionShock, SepticInterventionhydrocortisone sodium succinate; PlaceboPhasePhase 3Registry statusCompletedCombination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00002798 · start 1996-08
Registered record
- Registry ID
- NCT00002798
- Conditions
- Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Secondary Myelodysplastic Syndromes; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- asparaginase; daunorubicin hydrochloride; fludarabine phosphate; therapeutic hydrocortisone; allogeneic bone marrow transplantation; 3-dimensional conformal radiation therapy; filgrastim; cytarabine; idarubicin; dexamethasone; thioguanine; etoposide; methotrexate; cyclophosphamide; aldesleukin; busulfan
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1996-08
- Completion
- Not recorded
- Enrolment
- 880
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChildhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b) +12 moreInterventionasparaginase; daunorubicin hydrochloride; fludarabine phosphate; therapeutic hydrocortisone +12 morePhasePhase 3Registry statusCompletedThree Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
NCT00001521 · start 1995-06-08
Registered record
- Registry ID
- NCT00001521
- Conditions
- Congenital Adrenal Hyperplasia (CAH)
- Interventions
- Fludrocortisone; Hydrocortisone; Letrozole; Flutamide; Testolactone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1995-06-08
- Completion
- 2024-04-01
- Enrolment
- 66
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCongenital Adrenal Hyperplasia (CAH)InterventionFludrocortisone; Hydrocortisone; Letrozole; Flutamide +1 morePhasePhase 3Registry statusCompleted